Floatz logo

Orcagraft

Mixed Phenotype Acute Leukemia

Orca Biosystems, Inc.Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

71 Active assets in the Mixed Phenotype Acute Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
St. Jude Children's Research Hospital
Phase 4BB
Cytosin-Arabinosid
Children's Oncology Group
Phase 4BB
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3BB
DEXAMETHASONE
St. Jude Children's Research Hospital
Phase 4BB
METHOTREXATE
Children's Oncology Group
Phase 4BB

View all 50 →

Same molecule, other indications

Orcagraft is also rated in:

myelodysplastic syndromeDormant
C
Indicative ·
37 / 100
View asset →
acute lymphoblastic leukemiaDormant
C
Indicative ·
37 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →